TABLE 4.
Clinical follow-up of patients with ABMR and DSA compared to ABMR without HLA-DSA (left) and to non-ABMR with HLA-DSA (right).
| ABMR+ DSA+ (n = 31) | ABMR+ DSA– (n = 16) | P-value | ABMR– DSA+ (n = 17) | P-value vs. ABMR+ DSA+ | |
| 1-year follow-up post-biopsy | (n = 26) | (n = 14) | 0.45 | (n = 17) | 0.004 |
| Serum creatinine [mg/dl, mean (SD)] | 1.8 (0.7) | 2.0 (0.9) | 0.55 | 1.3 (0.3) | 0.040 |
| eGFR [ml/min, mean (SD)] | 45.2 (23.1) | 40.5 (24.6) | 0.88 | 57.0 (13.2) | 0.042 |
| Pr/Cr [mg/g, median (IQR)] | 258.0 (80–946) | 609.5 (73–1077) | 123.0 (70–214) | ||
| 4–5 years follow-up post-biopsy | (n = 19) | (n = 9) | 0.71 | (n = 10) | 0.043 |
| Serum creatinine [mg/dl, mean (SD)] | 2.0 (1.1) | 1.8 (0.6) | 0.51 | 1.4 (0.4) | 0.17 |
| eGFR [ml/min, mean (SD)] | 43.7 (22.7) | 37.9 (17.8) | 0.19 | 54.7 (13.8) | 0.002 |
| Pr/Cr [mg/g, median (IQR)] | 521.5 (122–1527) | 202.0 (84–474) | 70.0 (58–88) | ||
| Time of follow-up after biopsy (months) [median (IQR)] | 69.9 (25–95) | 50.3 (26–58) | 0.19 | 70.8 (39–91) | 0.87 |
| Death censored-graft loss [n (%)] | 13/31 (41.9%) | 6/16 (37.5%) | 1.00 | 0/17 (0%) | 0.002 |
| Graft loss including death [n (%)] | 16/31 (51.6%) | 9/16 (56.3%) | 1.00 | 2/17 (11.8%) | 0.011 |
| Subsequent biopsy with ABMR [yes (%)]# | (n = 12) 11/12 (91.7%) |
(n = 6) 4/6 (66.7%) |
0.25 | (n = 6) 2/6 (33.3%) |
0.022 |
ABMR, antibody-mediated rejection; DSA, HLA donor specific antibodies; eGFR, estimated glomerular filtration rate; IQR, interquartile range; Pr/Cr, urinary protein to creatinine ratio; SD, standard deviation. #From 24 patients with a subsequent biopsy realized. A significant p-value is indicated by a bold value.